目的 探讨强肝胶囊联合多烯磷脂酰胆碱治胶囊治疗代谢相关脂肪性肝病的临床疗效。方法 选取2021年1月—2023年3月石家庄市第二医院收治的96例代谢相关脂肪性肝病患者，按照随机数字表法将96例患者分为对照组和治疗组，每组各48例。对照组口服多烯磷脂酰胆碱胶囊，2粒/次，3次/d。治疗组在对照组基础上口服强肝胶囊，5粒/次，2次/d，连续治疗6 d后停1 d。两组患者连续治疗8周。观察两组的临床疗效，比较两组的体征指标、肝功能和血清炎症指标。结果 治疗后，治疗组的总有效率为93.75%，对照组的总有效率为79.17%，组间比较差异有统计学意义（P＜0.05）。治疗后，两组的体质量指数（BMI）、腰围显著降低，肝/脾CT比值显著升高（P＜0.05），且治疗组的BMI、腰围低于对照组，肝/脾CT比值高于对照组（P＜0.05）。治疗后，两组的γ-谷氨酰转肽酶（γ-GT）、天门冬氨酸氨基转移酶（AST）、丙氨酸氨基转移酶（ALT）水平显著降低（P＜0.05），且治疗组的γ-GT、AST、ALT水平明显低于对照组（P＜0.05）。治疗后，两组血清转化生长因子-β（TGF-β）、肿瘤坏死因子-α（TNF-α）、血清铁蛋白（SF）水平显著降低（P＜0.05），且治疗组的血清TGF-β、TNF-α、SF水平低于对照组（P＜0.05）。结论 强肝胶囊联合多烯磷脂酰胆碱可提高代谢相关脂肪性肝病的疗效，有助于改善肝功能，降低肥胖体征，减轻炎症反应。

Objective To investigate the clinical effect of Qianggan Capsules combined with Polyene Phosphatidylcholine Capsules in treatment of metabolically associated fatty liver disease. Methods Patients (96 cases) with metabolically associated fatty liver disease in Shijiazhuang Second Hospital from January 2021 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 48 cases. Patients in the control group were po administered with Polyene Phosphatidylcholine Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Qianggan Capsules on the basis of the control group, 5 grains/time, twice daily, after continuous treatment for 6 d, stop for 1 d. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and physical indicators, liver function, and serum inflammatory indicators in two groups were compared. Results After treatment, the total effective rate of patients in the treatment group was 93.75%, while that in the control group was 79.17%, and the difference between the groups was statistically significant (P < 0.05). After treatment, BMI and waist circumference of two groups were significantly decreased, while the liver/spleen CT ratio of two groups were significantly increased (P < 0.05). BMI and waist circumference of the treatment group were lower than those of the control group, while the liver/spleen CT ratio of the treatment group was higher than that of the control group (P < 0.05). After treatment, the levels of γ-GT, AST, and ALT in two groups were significantly reduced (P < 0.05), and the levels of γ-GT, AST, and ALT in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the serum levels of TGF-β, TNF-α, and SF in two groups were significantly reduced (P < 0.05), and the serum levels of TGF-β, TNF-α, and SF in the treatment group were lower than those in the control group (P < 0.05). Conclusion Qianggan Capsules combined with Polyene Phosphatidylcholine Capsules can improve the therapeutic effect of metabolically associated fatty liver disease, help to reduce inflammation, improve liver function, reduce obesity signs.

R977

河北省医学科学研究课题计划项目(20201350)